Stopped: Completion of MK-0431A-235 was rendered unnecessary, as the local oversight authority accepted in its stead the results of another study \[MK-0431-234\].
The primary objective of this study is to obtain safety information on the use of sitagliptin phosphate/metformin hydrochloride (HCl) (JANUMET®) from endocrinologists, diabetologists, internists, and general practitioners.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With an Adverse Event
Timeframe: Up to approximately 28 months
Age of Participants Prescribed Sitagliptin Phosphate/Metformin HCl
Timeframe: Up to approximately 28 months
Number of Participants With Concomitant Conditions
Timeframe: Up to approximately 28 months
Number of Participants Taking Concomitant Medications
Timeframe: Up to approximately 28 months